Diuretic usage in heart failure: a continuing conundrum in 2005.

@article{Gupta2005DiureticUI,
  title={Diuretic usage in heart failure: a continuing conundrum in 2005.},
  author={S. Gupta and L. Neyses},
  journal={European heart journal},
  year={2005},
  volume={26 7},
  pages={
          644-9
        }
}
Several large well-designed clinical trials have shown that the use of diuretics is beneficial in patients with hypertension. However, similarly robust data regarding their role in chronic heart failure are lacking. Historically, diuretics were developed for treatment of sodium and water retention in oedematous disorders and clinically, they remain the most potent drugs available to relieve symptoms and eliminate oedema in the congested patient with heart failure. In the non-congested patient… Expand
Beyond diuretics: management of volume overload in acute heart failure syndromes.
TLDR
Effective monitoring of volume status with newer modalities may allow more selective use of diuretics and diuretic-like modalities, but additional randomized trial data are clearly needed to establish ideal strategies to promote volume removal in acute HF syndromes. Expand
Loop diuretics and ultrafiltration in heart failure
TLDR
An unmet clinical need is highlighted for evidence-based algorithms, potentially using not only the classical clinical signs and symptoms of congestion as well as the estimated glomerular filtration rate and serum electrolytes, but also biomarkers of congestion/decongestion, neurohumoural activation or urinary kidney injury molecules, in order to optimize both loop diuretics and renin–angiotensin–aldosterone system blocker use in HF patients. Expand
ractical Applications of Intravenous Diuretic Therapy in ecompensated Heart Failure
ntravenous (IV) loop diuretics play an important role in the treatment of decompensated heart failure DHF). They inhibit the Na -K -2Cl reabsorptive pump in the thick ascending limb of the loop ofExpand
Practical applications of intravenous diuretic therapy in decompensated heart failure.
TLDR
Questions regarding the use of intravenous diuretic agents in patients with DHF are still unanswered, and there remains a compelling need for well-designed randomized, controlled clinical trials to establish appropriate treatment regimens that maximize therapeutic benefit while minimizing morbidity and mortality. Expand
Loop diuretic therapy in left ventricular systolic dysfunction: has familiarity bred contempt for a critical but potentially nephrotoxic cardio renal therapy?
TLDR
Loop diuretic therapy is at the heart of the management of this critical setting and may play a role in the cycle of decline given its independent but unclear linkage to cardiac death. Expand
Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization.
TLDR
The purpose of this review was to update the current status of studies with the available AVP antagonists and offer the possibility of added efficacy in relieving congestion and improving symptoms with minimal adverse effects in combination with standard medical therapy. Expand
Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF
TLDR
This trial aims to clarify features and contemplate whether continuous infusion is better than an intermittent strategy in terms of decongestion efficacy, diuretic efficiency, renal function, and long‐term prognosis. Expand
Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction
Intravenous loop diuretics are still the cornerstone of therapy in acute decompensated heart failure, however, the optimal dosage and administration strategies remain poorly defined particularly inExpand
Decongestive treatment of acute decompensated heart failure: cardiorenal implications of ultrafiltration and diuretics.
TLDR
Key clinical studies addressing the comparative impact of diuretic and ultrafiltration on important clinical outcomes and adverse effects, including decreased kidney function are served as a summary. Expand
EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan
TLDR
An overview of a new compound, tolvaptan, an oral selective V2-vasopressin antagonist, in light of the recently published Efficacy of Vasoppressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Diuretics in chronic heart failure — benefits andhazards
TLDR
As only limited data are available on improved prognosis with diuretics, long-term randomized mortality trials should be conducted, and the recent TORIC study may be the first step in this direction. Expand
Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure—A placebo-controlled trial
TLDR
The diuretic monotherapy of congestive heart failure with piretanide is highly effective and shows a significant improvement in all clinical and hemodynamic parameters in the absence of any remarkable side effects. Expand
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
TLDR
Diuretics bring about a considerable clinical improvement in patients with chronic heart failure but they stimulate the renin-angiotensin system, which occurs as a response to diuretic treatment rather than as a result of the disease process itself. Expand
Effect of diuretic therapy on hypertensive left ventricular hypertrophy.
TLDR
This review provides a critical examination of the available data on both sides of the question and concludes that there is no universal agreement on the influence of diuretics on LVH in hypertension. Expand
The acute vascular effects of frusemide in heart failure.
TLDR
The effect of frusemide on veins has been shown to be mostly an indirect one, but frusemides may also display direct venodilator properties, which is widely believed to occur due to the release of prostaglandins by the veins. Expand
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
TLDR
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor. Expand
Loop diuretics : translating pharmacokinetic properties into improved clinical outcomes
TLDR
Overall these data indicate that the complete and predictable absorption of torasemide extrapolates to improved clinical outcome in patients with CHF. Expand
Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy.
TLDR
The feasibility of discontinuing diuretic drugs in certain patients with stable CHF is demonstrated and predicts those patients likely to require reinitiation of therapy are predicted. Expand
Haemodynamic effects of diuretics in heart failure.
The organic mercurials have been known to have a diuretic effect since the sixteenth century, but their use for treating dropsy first began in 1920 in Vienna, when it was realised that a mercuryExpand
Continous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure
TLDR
Haemodynamic changes due to increased volume load can be detected with an implantable haemodynamic monitor and provide useful information for tailoring an optimal diuretic dose in patients with congestive heart failure. Expand
...
1
2
3
4
5
...